AI-designed drug for inflammatory bowel disease enters human clinical trials: 'A significant need'

Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. -- and a new artificial intelligence-generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed IBD drug -- ISM5411 -- has entered Phase I clinical trials. This is Insilico's fifth AI-designed drug to enter the pipeline. WHAT IS ARTIFICIAL INTELLIGENCE (AI)? If approved, it would be the first medication to treat IBD by blocking prolyl hydroxylase domain (PHD), a protein that regulates the body's gut barrier protection genes, according to Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.